J
Judith Michels
Researcher at Institut Gustave Roussy
Publications - 52
Citations - 4346
Judith Michels is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 36 publications receiving 3498 citations. Previous affiliations of Judith Michels include Université Paris-Saclay & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Molecular mechanisms of cisplatin resistance
Lorenzo Galluzzi,Laura Senovilla,Laura Senovilla,Laura Senovilla,Ilio Vitale,Ilio Vitale,Ilio Vitale,Judith Michels,Judith Michels,Judith Michels,Isabelle Martins,Isabelle Martins,Isabelle Martins,Oliver Kepp,Oliver Kepp,Oliver Kepp,Maria Castedo,Maria Castedo,Maria Castedo,Guido Kroemer +19 more
TL;DR: A systematic discussion of the mechanisms that account for the cisplatin-resistant phenotype of tumor cells are described and the development of chemosensitization strategies constitute a goal with important clinical implications.
Journal ArticleDOI
Systems biology of cisplatin resistance: past, present and future
Lorenzo Galluzzi,Ilio Vitale,Judith Michels,Catherine Brenner,Gyorgy Szabadkai,A Harel-Bellan,Maria Castedo,Guido Kroemer +7 more
TL;DR: Recent systems biology studies aimed at deconvoluting the complex circuitries that underpin cisplatin resistance are discussed, and how their findings might drive the development of rational approaches to tackle this clinically relevant problem.
Journal ArticleDOI
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao,Rona Yaeger,Vanessa Rodrik-Outmezguine,Anthony Tao,Neilawattie M. Torres,Matthew T. Chang,Matthew T. Chang,Matthias Drosten,Huiyong Zhao,Fabiola Cecchi,Todd Hembrough,Judith Michels,Judith Michels,Hervé Baumert,Linde A. Miles,Linde A. Miles,Naomi Campbell,Elisa de Stanchina,David B. Solit,Mariano Barbacid,Barry S. Taylor,Neal Rosen +21 more
TL;DR: Three distinct functional classes of BRAF mutants in human tumours are defined—those that have impaired kinase activity or are kinase-dead, whose activation of signalling is RAS-dependent, and those that activate ERK signalling by different mechanisms that dictate their sensitivity to therapeutic inhibitors of the pathway.
Journal ArticleDOI
Cisplatin resistance associated with PARP hyperactivation.
Judith Michels,Ilio Vitale,Lorenzo Galluzzi,Julien Adam,Ken A. Olaussen,Oliver Kepp,Laura Senovilla,Ibtissam Talhaoui,Justine Guegan,David Enot,Monique Talbot,Angélique Robin,Philippe Girard,Cedric Orear,Delphine Lissa,Abdul Qader Sukkurwala,Pauline Garcia,Parviz Behnam-Motlagh,Kimitoshi Kohno,Gen Sheng Wu,Catherine Brenner,Philippe Dessen,Murat Saparbaev,Jean-Charles Soria,Maria Castedo,Guido Kroemer +25 more
TL;DR: It is shown that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin, becoming susceptible to PARP inhibitor-induced apoptosis.
Journal ArticleDOI
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Soizick Mesnage,Aurélie Auguste,Catherine Genestie,Ariane Dunant,Erwann Pain,Françoise Drusch,Sebastien Gouy,P. Morice,E. Bentivegna,Catherine Lhommé,Patricia Pautier,Judith Michels,A. Le Formal,Bianca Cheaib,Julien Adam,Alexandra Leary +15 more
TL;DR: In EOC, sTILs levels are prognostic at diagnosis and remain prognostic after NACT, and TILs and PD-L1 expression increase following NACT.